Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. [PDF]
J Clin Hypertens (Greenwich), 2017 The efficacy and safety of azilsartan medoxomil (AZL‐M) were evaluated in African‐American patients with hypertension in a 6‐week, double‐blind, randomized, placebo‐controlled trial, for which the primary end point was change from baseline in 24‐hour mean systolic blood pressure (BP). There were 413 patients, with a mean age of 52 years, 57% women, and
Johnson W +9 more
europepmc +2 more sources
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension [PDF]
Clinical Hypertension, 2018 Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week ...
Attila Juhasz +4 more
doaj +2 more sources
Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
Clinical Therapeutics, 2011 Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for hypertension management.The purpose of this study was to review the pharmacology, pharmacokinetics, efficacy, safety profile, and role of azilsartan for hypertension management.Peer-reviewed clinical trials, review ...
, Kathy Zaiken
exaly +6 more sources
Open Chemistry, 2021 Five various chemometric methods were established for the simultaneous determination of azilsartan medoxomil (AZM) and chlorthalidone in the presence of azilsartan which is the core impurity of AZM.
Ahmed H Bakheit +2 more
exaly +2 more sources
MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
Российский кардиологический журнал, 2017 Modern approaches to antihypertension therapy suppose the usage of combination drugs, making significant positive influence on the values of systemic blood pressure (BP) in daily and nocturnal periods, optimization of 24-hour BP profile, achieved target ...
V. V. Skibitsky, A. V. Fendrikova
doaj +3 more sources
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. [PDF]
J Clin Hypertens (Greenwich), 2017 This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs fixed‐dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160–190 mm Hg).
Neutel JM +4 more
europepmc +4 more sources
Spectrophotometric and spectrofluorimetric studies on azilsartan medoxomil and chlorthalidone to be utilized in their determination in pharmaceuticals. [PDF]
Anal Chem Insights, 2014 The recently approved angiotensin II receptor blocker, azilsartan medoxomil (AZL), was determined spectrophotometrically and spectrofluorimetrically in its combination with chlorthalidone (CLT) in their combined dosage form. The UV-spectrophotometric technique depends on simultaneous measurement of the first derivative spectra for AZL and CLT at 286 ...
Ebeid WM +4 more
europepmc +4 more sources
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. [PDF]
J Clin Hypertens (Greenwich), 2018 An open‐label, long‐term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL‐M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up‐titrated (AZL‐M/CLD to 40/25
Bakris GL +6 more
europepmc +4 more sources
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. [PDF]
Blood Press Monit, 2014 The aim of the study was to measure the effects on blood pressure (BP) of the angiotensin receptor blocker azilsartan medoxomil, in 40 and 80 mg doses, combined with 5 mg of the calcium channel blocker amlodipine and to compare these effects with placebo plus amlodipine 5 mg.This was a randomized, controlled, double-blind study of 6 weeks' duration in ...
Weber MA +6 more
europepmc +4 more sources
The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. [PDF]
J Clin Hypertens (Greenwich), 2011 The current study assesses the antihypertensive efficacy and safety of the investigational angiotensin receptor blocker (ARB), azilsartan medoxomil (AZL‐M), compared with placebo and the ARB olmesartan medoxomil (OLM‐M). This randomized, double‐blind, placebo‐controlled, multicenter study assessed change from baseline in mean 24‐hour ambulatory ...
Bakris GL +7 more
europepmc +4 more sources